Correlation of clinic pathology characteristic with disease free survival and 5 years survival in stage iii-iv cervical cancer in low resource setting hospital

Pratama, Dito Oktawijaya; Tjokroprawiro, Brahmana Askandar; Handayani, Lulus

doi:10.48309/ecc.2024.424810.1732

Articles in Press

Document Type : Original Research Article

Authors

¹ Department of Obstetrics and Gynaecology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

² Department of Radiotherapy, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

10.48309/ecc.2024.424810.1732

Abstract

The aims of this article was to determine the correlation among clinical characteristics and therapeutic treatments on disease free survival (DFS) and 5 years survival in stage III-IV cervical cancer patients with limited radiotherapy facility. This was a retrospective cohort study of all patients admitted to our hospital from 2016-2022. Data on clinical characteristics were collected from medical records. Statistical analysis was performed to determine the relationship between therapeutic treatments and clinical characteristics, including age, histopathology, tumor size, and patient outcomes. Total sample was 216 patients. Patient with tumor size <6 cm had better survival rate and DFS than tumor size >6 cm (24 months vs. 21 months and 22 months vs. 12 months), radiotherapy waiting list <4 months showed better survival rate and DFS than patients who waited >4 months (33 months vs. 24 months and 24 months vs. 16 months), patients who received chemotherapy while waiting for radiotherapy had better survival rate and DFS than patients who did not (24 months vs. 10 months and 22 months vs. 10 months), and patients who continued ER AFL had better survival rate and DFS than patients who just received ER (44 months vs. 24 months and 34 months vs. 16 months). Tumor size, radiotherapy waiting list, chemotherapy administration, and type of radiotherapy are the most significant factors for outcome patients of stage III-IV cervical cancer.

Graphical Abstract

Keywords

Main Subjects

Cancer research

References

[1] a) I.G.A.S.M. Dewi, N.P. Sriwidyani, N.P. Ekawati, The role of epidermal growth factor receptor as progression factor in cervical intraepithelial neoplasia and squamous cell carcinoma, Bali Medical Journal, 2021, 10, 238-242. [Crossref], [Google Scholar], [Publisher], b) P.A. Kalvanagh, Y.A. Kalvanagh, Evaluation of the effects of siRNA on Snail1 and miR-143 gene expression levels in metastatic female breast cancer cells during mastectomy, International Journal of Advanced Biological and Biomedical Research, 2023, 11, 56-64. [Crossref], [Pdf], [Publisher], c) S. Zain Al Abdeen, Y. Mustafa, S. Mutlag, Synthesis of disubstituted anisolodipyrone-derived ester compounds: The search for new bioactive candidates, Journal of Medicinal and Pharmaceutical Chemistry Research, 2022, 4, 1171-1183. [Crossref], [Google Scholar], [Publisher] d) S. Zain Al Abdeen, Y. Mustafa, S. Mutlag, Synthesis and biomedical activities of novel multifunctional benzodipyrone-based derivatives, Journal of Medicinal and Pharmaceutical Chemistry Research, 2022, 4, 938-949. [Crossref], [Google Scholar], [Publisher]

[2] H. Udiyanto, A. Mudigdo, S. Sulistyowati, B. Purwanto, V. Widyaningsih, B. Wasita, A cohort study: caspase-3 as prognostic factor of radiation therapy in the advanced stage of cervical cancer (IIB-IIIB) patients, Bali Medical Journal, 2020, 9, 2, 501-503. [Crossref], [Google Scholar], [Publisher]

[3] A) B. Wasita, Suyatmi., R.N. Pesik, R.D. Yudhani, N. Wiyono, R.F. Rahayu, K.Y. Yarso, High-risk human papillomavirus prevalence among patients with cervical cancer at Moewardi General Hospital in Surakarta, Indonesia, Bali Medical Journal, 2023, 12, 2, 1918-1921. [Crossref], [Google Scholar], [Publisher], b) A.B. Taha, M.S. Essa, B. T.Chiad, Spectroscopic study of iron oxide nanoparticles synthesized via hydrothermal method, Chemical Methodologies, 2022, 6, 977-984. [Crossref], [Google Scholar], [Publisher], c) F.A. Hiawi, I.H. Ali, Study the adsorption behavior of food colorant dye Indigo Carmine and Loratadine Drug in aqueous solution, Chemical Methodologies, 2022, 6, 720-730. [Crossref], [Google Scholar], [Publisher] d) E. Golipour-Chobar, F. Salimi, G. Ebrahimzadeh-Rajaei, Sensing of lomustine drug by pure and doped C48 nanoclusters: DFT calculations, Sensors, 2022, 6, 790-800. [Crossref], [Google Scholar], [Publisher]

[4] I.G.A.S. Mahendra-Dewi, I.K. Suwiyoga, E. Joewarini, I.G. Alit-Artha, High Interleukin-6, low CD4+ and CD8+ T-lymphocytes expressions as risk factors of cervical carsinoma infected by human papilloma virus type-52, Indonesia J. Biomed. Sci., 2013, 7, 2, 57-62. [Google Scholar], [Publisher]

[5] I.G. Mahendra-Dewi, I.K. Suwiyoga, THE RISK OF SQUAMOUS CELL CARCINOMA ON HUMAN PAPILLOMAVIRUS TYPE-16 INFECTION IN BALI. Indonesia Journal of Biomedical Science, 2013, 7, 27-29. [Google Scholar], [Publisher]

[6] Y. Li, Z. Chen, X. Wang, X. Li, J. Zhou, Y. Zhang Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy. BMC cancer, 2021, 21, 1-15 [Crossref], [Google Scholar], [Publisher]

[7] R.L. Siegel, K.D. Miller, H.E. Fuchs, A. Jemal, Cancer statistics, Ca Cancer J Clin, 2022, 72, 7-33. [Crossref], [Google Scholar], [Publisher]

[8] B. Budiman, Y.M. Hidayat, Evaluasi Program Deteksi Dini Kanker Serviks dengan Metode See and Treat di Kabupaten Karawang. Indones. J. Obstet. Gynecol. Sci, 2019, 2, 72-80. [Crossref], [Google Scholar], [Publisher]

[9] E. Chereau, C. Hseraye, M. Ballester, L. Monnier, R. Rouzier, E. Touboul, E. Daraï, The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer. Anticancer research, 2013, 33, 1661-1666. [Google Scholar], [Publisher]

[10] W.R. Brewster, P.J. DiSaia, B.J. Monk, A. Ziogas, S.D. Yamada, H. Anton-Culver, Young age as a prognostic factor in cervical cancer: results of a population-based study. American journal of obstetrics and gynecology, 1999, 180, 1464-1467. [Crossref], [Google Scholar], [Publisher]

[11] B.A. Quinn, X. Deng, A. Colton, D. Bandyopadhyay, J. Carter, J., E.C. Fields, Increasing age predicts poor cervical cancer prognosis with subsequent effect on treatment and overall survival. Brachytherapy, 2019, 18, 29-37. [Crossref], [Google Scholar], [Publisher]

[12] G. Tognon, M. Carnazza, M. Ragnoli, S. Calza, F. Ferrari, A. Gambino, V. Zizioli, S. Notaro, B. Sostegni, E. Sartori, Prognostic factors in early-stage ovarian cancer, Ecancermedicalscience, 2013, 13, 325. [Crossref], [Google Scholar], [Publisher]

[13] N. Singh, S. Arif, Histopathologic parameters of prognosis in cervical cancer–a review. International Journal of Gynecologic Cancer, 2004, 14, 5, 741-750. [Crossref], [Google Scholar], [Publisher]

[14] N. Hossain, R. Perveen, M.S. Mahmud, M.K. Hassan, Prognostic Impact of Histopathology in Patients with Advanced Stage Cervical Carcinoma Treated with Radiotherapy. Journal of Bangladesh College of Physicians & Surgeons, 2019, 37, 175-180. [Crossref], [Google Scholar], [Publisher]

[15] A. Soderini, A. Aragona, A. Quintaie, H. Moschen, M. Mendez, Prognostic significance of the Central Tumor Size (CTS) in Cervical Cancer (CC) stages IIb and IIIb: What should we do with the FIGO staging system and therapeutic strategies?, Archives of Cancer Science and Therapy, 2021, 5, 2-5. [Crossref], [Google Scholar], [Publisher]

[16] C. Sun, S. Wang, W. Ye, R. Wang, M. Tan, H. Zhang, J. Zhou, M. Li, L. Wei, P. Xu, G. Zhu, J. Lang, S. Lu, The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer. Frontiers in oncology, 2022, 12, 934110. [Crossref], [Google Scholar], [Publisher]

[17] Y. Todo, H. Watari, Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups. Chinese Journal of Cancer Research, 2016, 28, 221-227. [Crossref], [Google Scholar], [Publisher]

[18] K.N. Lohlun, J.A. Kotzen, R. Lakier, A prospective study on the impact of waiting times for radiotherapy for cervical cancer at Charlotte Maxeke Johannesburg Academic Hospital, South Africa, South African Journal of Obstetrics and Gynaecology, 2015, 21, 11, 6-9. [Crossref], [Google Scholar], [Publisher]

[19] K.W. Noh, B. Kim, C.H. Choi, T.-J. Kim, J.-W. Lee, B.-G. Kim, D.-S. Bae, W.K. Cho, W. Park, Y.-Y. Lee, Effect of waiting time from pathological diagnosis to definitive concurrent chemoradiation for cervical cancer on overall survival. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 2022, 54, 245-252. [Crossref], [Google Scholar], [Publisher]

[20] Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration, Neoadjuvant chemotherapy for locally advanced cervical cancer: a systemic review and meta-analiysis of individual patient data from 21 randomized trials, Eur. J. Cancer, 2003, 39, 2470-2486 [Crossref], [Google Scholar], [Publisher]

[21] J.E. Sardi, C.E. Sananes, A.A. Giaroli, A. Bermúdez, M.H. Ferreira, A.H. Soderini, L. Snaidas, N. Guardodo, P. Anchezar, O.C. Ortiz, G.R. di PaolaNeoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. International Journal of Gynecological Cancer, 1998, 8, 441-450. [Crossref], [Google Scholar], [Publisher]

[22] L. Rydzewska, J. Tierney, C.L. Vale, P.R. Symonds, Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database of Systematic Reviews, 2010, 20, 1. [Crossref], [Google Scholar], [Publisher]

[23] R. Banerjee, M. Kamrava, Brachytherapy in the treatment of cervical cancer: a review. International journal of women's health, 2014, 6, 555-564. [Crossref], [Google Scholar], [Publisher]

[24] W.J. Koh, N.R. Abu-Rustum, S. Bean, K. Bradley, S.M. Campos, K.R. Cho, H.S. Chon, C. Chu, R. Clark, D. Cohn, M.A. Crispens, Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2019, 17, 64-84. [Crossref], [Google Scholar], [Publisher]

[25] M. Abdel-Wahab, S. Grover, E.H. Zubizarreta, J.A. Rubio, Addressing the burden of cervical cancer through IAEA global brachytherapy initiatives. Brachytherapy, 2020, 19, 850-856. [Crossref], [Google Scholar], [Publisher]

[26] A.N., Viswanathan, S. Beriwal, J.F. De Los Santos, D.J. Demanes, D. Gaffney, J. Hansen, E. Jones, C. Kirisits, B. Thomadsen, B. Erickson, American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy, 2012, 11, 47-52. [Crossref], [Google Scholar], [Publisher]

[27] V.T. Nguyen, S. Winterman, M. Playe, A. Benbara, L. Zelek, F. Pamoukdjian, G. Bousquet, Dose-intense cisplatin-based neoadjuvant chemotherapy increases survival in advanced cervical cancer: An up-to-Date meta-analysis. Cancers, 2022, 14, 842. [Crossref], [Google Scholar], [Publisher]

[28] Y.-P. Liu, C.-C. Zheng, Y.-N. Huang, M.-L. He, W.W. Xu, B. Li, Molecular mechanisms of chemo‐and radiotherapy resistance and the potential implications for cancer treatment, MedComm, 2021, 2, 3, 315-340. [Crossref], [Google Scholar], [Publisher]

Eurasian Chemical Communications

Correlation of clinic pathology characteristic with disease free survival and 5 years survival in stage iii-iv cervical cancer in low resource setting hospital

References

References

Articles in Press, Accepted Manuscript
Available Online from 27 November 2023

Correlation of clinic pathology characteristic with disease free survival and 5 years survival in stage iii-iv cervical cancer in low resource setting hospital

References

References

Articles in Press, Accepted Manuscript Available Online from 27 November 2023

Articles in Press, Accepted Manuscript
Available Online from 27 November 2023